Does the media prefer BEAM or CRSP?

In the previous week, Beam Therapeutics had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 4 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 1.17 beat CRISPR Therapeutics' score of -0.08 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to DNLI or BEAM?

In the previous week, Denali Therapeutics had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 7 mentions for Denali Therapeutics and 5 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Beam Therapeutics' score of 1.17 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EDIT or BEAM?

In the previous week, Editas Medicine and Editas Medicine both had 5 articles in the media. Beam Therapeutics' average media sentiment score of 1.17 beat Editas Medicine's score of 0.64 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BEAM or NTLA?

In the previous week, Beam Therapeutics and Beam Therapeutics both had 5 articles in the media. Intellia Therapeutics' average media sentiment score of 1.21 beat Beam Therapeutics' score of 1.17 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRME or BEAM?

In the previous week, Prime Medicine and Prime Medicine both had 5 articles in the media. Beam Therapeutics' average media sentiment score of 1.17 beat Prime Medicine's score of 0.90 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Beam Therapeutics (BEAM) Competitors

$29.76 +1.37 (+4.83%)

As of 08/21/2026 04:00 PM Eastern

Compare

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

Should you buy Beam Therapeutics stock or one of its competitors? Beam Therapeutics's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Prime Medicine (PRME). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Beam Therapeutics compare to CRISPR Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Beam Therapeutics currently has a consensus target price of $49.00, suggesting a potential upside of 64.65%. CRISPR Therapeutics has a consensus target price of $68.06, suggesting a potential upside of 14.38%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

Beam Therapeutics has a net margin of -54.75% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.00	-$79.99M	-$0.86	N/A
CRISPR Therapeutics	$3.51M	1,639.05	-$581.60M	-$4.76	N/A

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Beam Therapeutics had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 4 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 1.17 beat CRISPR Therapeutics' score of -0.08 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Beam Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A
Beam Therapeutics	$139.74M	22.00	-$79.99M	-$0.86	N/A

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Denali Therapeutics presently has a consensus target price of $35.92, indicating a potential upside of 44.13%. Beam Therapeutics has a consensus target price of $49.00, indicating a potential upside of 64.65%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Denali Therapeutics had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 7 mentions for Denali Therapeutics and 5 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Beam Therapeutics' score of 1.17 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

Summary

Denali Therapeutics and Beam Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Editas Medicine has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

In the previous week, Editas Medicine and Editas Medicine both had 5 articles in the media. Beam Therapeutics' average media sentiment score of 1.17 beat Editas Medicine's score of 0.64 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has a net margin of -54.75% compared to Editas Medicine's net margin of -157.32%. Beam Therapeutics' return on equity of -30.71% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Editas Medicine presently has a consensus price target of $5.50, indicating a potential upside of 76.85%. Beam Therapeutics has a consensus price target of $49.00, indicating a potential upside of 64.65%. Given Editas Medicine's higher probable upside, research analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	11.79	-$160.06M	-$0.75	N/A
Beam Therapeutics	$139.74M	22.00	-$79.99M	-$0.86	N/A

Summary

Beam Therapeutics beats Editas Medicine on 12 of the 15 factors compared between the two stocks.

How does Beam Therapeutics compare to Intellia Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

In the previous week, Beam Therapeutics and Beam Therapeutics both had 5 articles in the media. Intellia Therapeutics' average media sentiment score of 1.21 beat Beam Therapeutics' score of 1.17 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus target price of $49.00, indicating a potential upside of 64.65%. Intellia Therapeutics has a consensus target price of $21.15, indicating a potential upside of 64.74%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Beam Therapeutics has a net margin of -54.75% compared to Intellia Therapeutics' net margin of -672.16%. Beam Therapeutics' return on equity of -30.71% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.00	-$79.99M	-$0.86	N/A
Intellia Therapeutics	$67.67M	26.59	-$412.69M	-$3.36	N/A

Summary

Beam Therapeutics beats Intellia Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Beam Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Prime Medicine currently has a consensus price target of $7.69, indicating a potential upside of 126.97%. Beam Therapeutics has a consensus price target of $49.00, indicating a potential upside of 64.65%. Given Prime Medicine's stronger consensus rating and higher probable upside, research analysts plainly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Beam Therapeutics has a net margin of -54.75% compared to Prime Medicine's net margin of -4,613.11%. Beam Therapeutics' return on equity of -30.71% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	132.80	-$201.14M	-$1.06	N/A
Beam Therapeutics	$139.74M	22.00	-$79.99M	-$0.86	N/A

Prime Medicine has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

In the previous week, Prime Medicine and Prime Medicine both had 5 articles in the media. Beam Therapeutics' average media sentiment score of 1.17 beat Prime Medicine's score of 0.90 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

Get Beam Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAM vs. The Competition

Export

Metric	Beam Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.07B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-34.60	11.62	272.60	24.24
Price / Sales	22.00	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	2.88	16.80	13.05	6.20
Net Income	-$79.99M	-$12.50M	$3.47B	$348.59M
7 Day Performance	11.25%	3.29%	2.09%	0.08%
1 Month Performance	14.86%	8.23%	6.64%	3.88%
1 Year Performance	78.85%	55.05%	25.02%	16.98%

Beam Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAM Beam Therapeutics	2.1691 of 5 stars	$29.76 +4.8%	$49.00 +64.7%	+78.8%	$3.07B	$139.74M	N/A	510	Positive News
CRSP CRISPR Therapeutics	2.4542 of 5 stars	$54.28 +1.4%	$68.06 +25.4%	+9.5%	$5.18B	$3.51M	N/A	460	Positive News
DNLI Denali Therapeutics	3.3975 of 5 stars	$24.35 -0.2%	$35.92 +47.5%	+60.9%	$3.90B	$330.53M	N/A	430	News Coverage Positive News
EDIT Editas Medicine	2.359 of 5 stars	$2.84 +0.7%	$5.40 +90.1%	+11.1%	$433.10M	$40.52M	N/A	230	Analyst Forecast
NTLA Intellia Therapeutics	3.2438 of 5 stars	$12.09 +1.5%	$21.15 +75.0%	+22.1%	$1.67B	$59.51M	N/A	600	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAM) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Do analysts prefer BEAM or CRSP?

Which has more risk and volatility, BEAM or CRSP?

Is BEAM or CRSP more profitable?

Which has stronger earnings and valuation, BEAM or CRSP?

Do insiders and institutionals hold more shares of BEAM or CRSP?

Does the media prefer BEAM or CRSP?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Which has stronger valuation & earnings, DNLI or BEAM?

Is DNLI or BEAM more profitable?

Do insiders & institutionals believe in DNLI or BEAM?

Do analysts prefer DNLI or BEAM?

Does the media refer more to DNLI or BEAM?

Which has more risk & volatility, DNLI or BEAM?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Which has more volatility & risk, EDIT or BEAM?

Does the media refer more to EDIT or BEAM?

Do insiders and institutionals believe in EDIT or BEAM?

Is EDIT or BEAM more profitable?

Do analysts prefer EDIT or BEAM?

Which has better earnings and valuation, EDIT or BEAM?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Which has more volatility & risk, BEAM or NTLA?

Does the media prefer BEAM or NTLA?

Do analysts recommend BEAM or NTLA?

Is BEAM or NTLA more profitable?

Do institutionals & insiders have more ownership in BEAM or NTLA?

Which has preferable earnings and valuation, BEAM or NTLA?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Do analysts prefer PRME or BEAM?

Is PRME or BEAM more profitable?

Do institutionals and insiders have more ownership in PRME or BEAM?

Which has better valuation & earnings, PRME or BEAM?

Which has more risk & volatility, PRME or BEAM?

Does the media favor PRME or BEAM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools